Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Memorial Sloan-Kettering

Neither a doctor nor a teaching hospital

Research payments

$51,226,504

340 payments

Through program year 2025, Memorial Sloan-Kettering is reported as receiving $51,226,504 in research payments, across 340 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $7,706,157 39
2024 Research $6,937,645 34
2023 Research $7,407,298 39
2022 Research $8,732,671 31
2021 Research $9,895,839 38
2020 Research $7,021,618 65
2019 Research $3,525,274 94

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $47,802,710 199 payments
  2. Genentech, Inc. $1,953,126 75 payments
  3. EMD Serono Research & Development Institute, Inc. $415,261 5 payments
  4. EMD Serono, Inc. $378,973 4 payments
  5. Array BioPharma Inc. $163,421 23 payments
  6. Jazz Pharmaceuticals Inc. $104,505 3 payments
  7. Celgene Corporation $102,866 3 payments
  8. Immunomedics, Inc. $84,034 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $74,441 8 payments
  10. Mirati Therapeutics, Inc. $50,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (NHL) $9,884,242 5 payments
  2. A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (NHL) $5,196,040 6 payments
  3. A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (Loxo-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin Cll-322) $3,444,844 6 payments
  4. A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations $2,906,090 4 payments
  5. Study of Loxo-305 Versus Investigator's Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (SLL) (Bruin Cll-321) $1,842,850 3 payments
  6. A First in Human Phase 1A and 1B Trial to Assess the Safety Tolerability and Preliminary Efficacy of Ly4170156 An Antibody Drug Conjugate Targeting Folate Receptor A Expressing Tumor Cells in Participants With Selected Advanced Tumors $1,565,868 3 payments
  7. A Phase 1A/1B Study of Ly3537982 in Patients With Kras G12c-Mutant Advanced Solid Tumors $1,518,408 3 payments
  8. A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (NHL) $1,302,013 4 payments
  9. A Phase 1A/1B Study of Ly3484356 Administered As Monotherapy and in Combination With Abemaciclib to Patients With Er+, Her2- Locally Advanced Or Metastatic Breast Cancer $1,279,064 7 payments
  10. A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors, Including Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation (Libretto-001) $1,221,999 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record